Navigation Links
SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
Date:8/1/2013

Rancho Cordova, CA (PRWEB) August 01, 2013

SureClinical, a provider of cloud-based content management application software and services for health sciences, announced today that it has successfully completed an FDA 21 CFR Part 11 compliance audit of its SureTrial® eTMF clinical trials content management application. More information is available at http://www.SureTrial.com.

Conducted through a leading independent GxP process auditing organization, SureTrial’s successful audit will help sponsors, clinical research organizations, academic research organizations and investigator sites running clinical trials comply with FDA rules and regulations related to electronic records and electronic signatures used in Electronic Trial Master File, or eTMF implementations.

“SureTrial eTMF is the first eTMF cloud software solution that completely addresses FDA 21 CFR Part 11 regulations and that has successfully completed an independent audit and validation,” said Zack Schmidt, President and CEO of SureClinical. “With the independent audit and validation of SureTrial eTMF, life sciences organizations can accelerate their compliance and validation initiatives for faster application deployment, insuring higher levels of GxP process management with eTMF documents and medical images.”

The FDA 21 CFR Part 11 compliance audit was performed by a leading independent GxP process organization that provides training to industry and US FDA regulatory agency personnel on 21 CFR Part 11 regulated computerized systems. The audit covered requirements for electronic records and electronic signatures under 21 CFR Part 11.

About SureClinical

SureClinical is a provider of cloud-based content management application software for health sciences. Headquartered in the Northern California, SureClinical’s founders have proven expertise in delivering market leading enterprise applications in the health sciences and enterprise mobile computing areas. To find out more, visit http://www.SureClinical.com.

###

Trademarks
SureClinical, SureTrial®, SureTrial® eTMF are trademarks of SureClinical.

Copyright © 2013 SureClinical. All rights reserved. SureClinical, SureTrial eTMF and the SureTrial logo are trademarks of SureClinical. Other names used herein may be trademarks of their respective owners.

http://www.SureClinical.com
http://www.SureTrial.com

Read the full story at http://www.prweb.com/releases/2013/8/prweb10982140.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... ... 14, 2017 , ... Seattle-based Phase Genomics has announced the ... researchers around the globe. Long considered a “holy grail” in biological research, ... of scientific questions. The announcement was made today at the Plant & ...
(Date:1/13/2017)... ... January 13, 2017 , ... Two Kalamazoo entrepreneurs ... called fulvic acid that farms, greenhouses and hydroponics operations use to increase yields ... the fastest growing segments of customers using this high grade fulvic acid extracted ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit ... – a process that evaluates the patent estate of a company, its impact and ... a biomedical firm leading the way in technologies that transform energy sources such as ...
(Date:1/12/2017)... January 12, 2017 The Energy ... biggest facility for producing mycorrhizae. The Centre for Mycorrhizal ... potential of mycorrhizae and developed a technology that eventually ... ... The TERI facility has a production ...
Breaking Biology Technology:
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/12/2016)... CLEVELAND , Dec. 12, 2016  Researchers ... commercial possibilities for graphene by combining the material ... a highly sensitive pressure detector able to sense ... of a small spider.  The ... and can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):